Diabetes Mellitus, with Complications, Glomerulosclerosis, Pancreas Transplantation, Pancreatic Insufficiency (Exocrine and Endocrine), Renal Failure Chronic Requiring Dialysis, Transplantation, Kidney
Conditions
Keywords
SPK transplant, Simultaneous pancreas-kidney (SPK) transplant, Hypomagnesemia transplantation, Hypomagnesemia kidney transplant, Hypomagnesemia pancreas-kidney transplant, Hypomagnesemia simultaneous pancreas-kidney transplant
Brief summary
Magnesium is essential in human physiology. Simultaneous pancreas-kidney (SPK) transplant recipients frequently experience hypomagnesemia. The effects of hypomagnesaemia are harmful. This observational study assessed intraoperative magnesium supplementation's utility in patients undergoing SPK transplantation. Perioperative hemodynamics were monitored. Postoperative serum magnesium was monitored at 12 hours and 48 hours.
Detailed description
A vital component of human physiology is magnesium. It is common for recipients of simultaneous pancreas-kidney (SPK) transplants to have hypomagnesemia. The consequences of hypomagnesaemia are detrimental. This prospective observational study evaluated the effectiveness and safety of intraoperative magnesium supplementation in adult SPK transplant recipients. Arrhythmia and perioperative hemodynamics were observed. Serum magnesium levels were checked 12 and 48 hours after surgery.
Interventions
Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
Sponsors
Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)
Dr Olu Bamgbade, MD, FRCPC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Adult diabetic patients who require insulin therapy and hemodialysis due to pancreatic-kidney failure.
Exclusion criteria
* Adult diabetic patients who do not require insulin therapy and hemodialysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum magnesium levels. | 48 hours | Serum magnesium levels after surgery at 12 and 48 hours. |
| Perioperative cardiovascular incidents. | 48 hours | Incidence rate of intraoperative and postoperative dysrhythmia events for each patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative neurological incidents. | 48 hours | Incidence rate of postoperative confusion, muscle spasms, or weakness in each patient. |
Countries
United Kingdom
Outcome results
None listed